Bill Grossman has an extensive background in the development of cancer immunotherapies and joined Bellicum in 2018 from Genentech/Roche. In his most recent role at Genentech, Dr. Grossman served as the Group Medical Director, Cancer Immunotherapy, where he led the global clinical development of TECENTRIQ® in gastrointestinal cancers and of cancer immunotherapy combinations across all solid tumor types. Previously, he served as Senior Vice President, Research & Clinical Development at Biothera, and also held leadership positions in oncology and hematology research, clinical development, and medical affairs at AbbVie, Baxter Healthcare, and Merck & Co. Prior to joining the industry, he held various positions with the Medical College of Wisconsin and the Children’s Hospital of Wisconsin, and was Founder and Medical Director of the Clinical Immunodiagnostic and Research Laboratory, Professor for Microbiology and Genetics, and Director of the Hematology/Oncology/Bone Marrow Transplant Division for the Immunodeficiency Transplant Program. Dr. Grossman earned his M.D. and Ph.D. degrees from Washington University School of Medicine.